Companies / Jade Biosciences, Inc.
Jade Biosciences, Inc.
Nasdaq: JBIOCIK 1798749WALTHAM, MA
Financials
Ownership
63.6M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 0.85% | 538,382 |
| 10%+ / strategic | 8.55% | 5,436,870 |
| Institutions | 73.56% | 46,783,703 |
| Public float | 17.04% | 10,838,432 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 5
View all →| Insider | % of shares | Shares |
|---|---|---|
King Andrew JamesSee Remarks | 0.61% | 386,113 |
Frohlich TomCEOChief Executive Officer · Director | 0.14% | 86,331 |
Dahms Bradford D.Chief Financial Officer | 0.06% | 37,813 |
Balta ElizabethSee Remarks | 0.04% | 28,125 |
Dobmeier EricDirector | — | — |
Institutional holders 109
View all →| Holder | Value | % of shares |
|---|---|---|
| $106.38M | 10.84% | |
| $70.26M | 7.16% | |
| $62.25M | 4.40% | |
| $51.89M | 3.67% | |
| $51.58M | 5.77% | |
| $51.55M | 5.25% | |
| $49.69M | 5.06% | |
| $43.56M | 4.88% | |
| $35.06M | 2.48% | |
| $32.34M | 3.30% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | New | — | $43.56M | +3.1M | 3,105,669 4.88% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Add | — | $37.60M | +1.7M +263.23% | 2,335,285 3.67% of shares | medium |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | — | $5.65M | +402K | 402,489 0.63% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Trim | — | $-4.86M | -346K -65.17% | 185,011 0.29% of shares | low |
| Q2 2025 as of | Barclays PLC 13F manager | New | — | $2.75M | +275K | 274,830 0.43% of shares | low |
| Q1 2026 as of | Great Point Partners, LLC 13F manager | Add | — | $2.22M | +158K +19.62% | 964,462 1.52% of shares | low |
| Q3 2025 as of | Barclays PLC 13F manager | Trim | — | $-1.98M | -229K -83.35% | 45,767 0.07% of shares | low |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Trim | — | $-1.53M | -69K -2.40% | 2,801,451 4.40% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Janus Henderson Group PLC | Passive13G | — |
| Bellevue Group AG | Passive13G | — |
| Venrock Healthcare Capital Partners III, L.P. | Passive13G/A | — |
| Deep Track Capital, LP | Passive13G/A | — |
| Janus Henderson Group PLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| JBIO | — | 008064206 |